Subcutaneous semaglutide: Phase IIIa data

The open-label, international Phase IIIa SUSTAIN 4 trial in 1,089 Type II diabetics previously treated with metformin with or without a sulfonylurea showed that once-weekly 0.5 and 1 mg subcutaneous s...